Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
